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background: Patients with diabetes mellitus (DM) have enhanced platelet reactivity and reduced sensitivity to clopidogrel compared with non-DM 
patients. A multicenter, randomized, open-label crossover study in African American (AA) patients with stable coronary artery disease (CAD), showed 
that ticagrelor provides a faster onset and higher degree of platelet inhibition than clopidogrel.We report here a subgroup analysis comparing the 
antiplatelet effects in AAs with and without DM.
methods: AA patients with stable CAD were randomized to receive ticagrelor (180mg loading dose [LD], 90mg twice-daily maintenance dose [MD]) 
or clopidogrel (600mg LD, 75mg once-daily MD) for 7-9 days, plus ongoing aspirin treatment (75-100mg daily). Following a 10-14 day washout 
period, the alternative P2Y12 inhibitor was given. Patients were stratified according to DM status. The VerifyNow P2Y12 function assay was used to 
measure platelet reactivity.
results: Of the thirty-four patients randomized to treatment, 50% were diabetic. Overall, mean age was 62.3 (±6.7) years and 32.4% were female. 
In both the DM and non-DM subgroups, platelet reactivity was lower for ticagrelor vs clopidogrel at all post-dose time points (Table).
Conclusions: Ticagrelor provided a faster and greater extent of platelet inhibition than clopidogrel in both the DM and non-DM subgroups of AA 
patients with stable CAD.
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After LD
Time
Ticagrelor
DM
Mean (SD)
Clopidogrel
DM
Mean (SD)
Ticagrelor
Non-DM
Mean (SD)
Clopidogrel
Non-DM
Mean (SD)
n=17 n=15 n=13 n=13
Baseline 272.1 (44.0) 290.5 (48.9) 274.2 (57.5) 267.7 (60.1)
0.5 h 162.9 (100.5) 283.4 (56.8) 150.4 (94.6) 271.6 (60.5)
2 h 28.8 (33.8) 224.1 (72.3) 23.8 (20.8) 196.0 (81.2)
8 h 31.0 (26.5) 194.8 (82.5) 20.0 (22.7) 190.2 (73.9)
On Day 7 after MD
Time
Ticagrelor
DM
Mean (SD)
Clopidogrel
DM
Mean (SD)
Ticagrelor
Non-DM
Mean (SD)
Clopidogrel
Non-DM
Mean (SD)
0 h (pre-dose) 44.3 (40.3) 177.1 (75.8) 43.3 (49.3) 176.8 (57.6)
2 h 28.3 (31.8) 162.8 (82.1) 14.8 (17.4) 152.1 (66.5)
8 h 34.7 (38.2) 154.7 (64.5) 23.8 (25.7) 133.3 (74.3)
DM = diabetes mellitus; LD = loading dose; MD = maintenance dose
